<div id="readability-page-1"><p>Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares hit a new 52-week high during trading on Friday . The company traded as high as $25.59 and last traded at $25.46, with a volume of 93527 shares traded. The stock had previously closed at $22.31.</p><div><p><span></span><span>Get <strong>Lyell Immunopharma</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>A number of research analysts recently weighed in on LYEL shares. HC Wainwright  reaffirmed a &#34;neutral&#34; rating and set a $20.00 price objective (up previously from $10.00) on shares of Lyell Immunopharma in a research report on Monday, November 24th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Lyell Immunopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 1st. One analyst  has rated the stock with a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the company  has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.00.</p><p><b>Check Out Our Latest Report on LYEL</b></p><h2>Lyell Immunopharma Trading Up 14.1%</h2><p>The stock has a market capitalization of $540.21 million, a PE ratio of -1.11 and a beta of -0.11. The stock has a 50 day moving average price of $18.18 and a 200-day moving average price of $13.25. </p><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Research analysts forecast that  Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year. </p><h2>Hedge Funds Weigh In On Lyell Immunopharma</h2><p>Several large investors have recently added to or reduced their stakes in the company. ARCH Venture Management LLC increased its stake in shares of  Lyell Immunopharma by 51.5% in the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after purchasing an additional 938,438 shares in the last quarter.  Almitas Capital LLC increased its stake in  Lyell Immunopharma by 136.3% in the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares in the last quarter.  Vanguard Group Inc. raised its holdings in  Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company's stock valued at $12,651,000 after acquiring an additional 336,378 shares during the period.  Acadian Asset Management LLC grew its stake in  Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter.  Finally, Nuveen LLC bought a new stake in  Lyell Immunopharma in the 1st quarter valued at $345,000. Hedge funds and other institutional investors own  66.05% of the company's stock. </p><h2>About Lyell Immunopharma</h2> (Get Free Report)<p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p><h2>Read More</h2><ul><li>Five stocks we like better than Lyell Immunopharma</li><li>Investing in Commodities: What Are They? How to Invest in Them</li><li>Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So</li><li>How Investors Can Find the Best Cheap Dividend Stocks</li><li>The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy</li><li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li><li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p><p>While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LYEL

<p>Lyell Immunopharma (NASDAQ:LYEL) shares reached a new 52-week high, trading as high as $25.59. Despite the rise, analysts have mixed ratings, with a consensus "Reduce" rating and a $20.00 price target. The company reported better-than-expected earnings, but still faces significant financial challenges. Institutional investors have been adjusting their stakes, with 66.05% of the stock owned by them. Lyell Immunopharma focuses on developing T cell reprogramming technologies for solid tumors.</p>

Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High - Time to Buy?